Since the start of the pandemic, fear of drug shortages have been top of mind for companies that source active pharmaceutical ingredients from China. A recent FiercePharma article noted that India, the world’s largest maker of generic drugs, is investing in alternatives to Chinese APIs. The Indian government is establishing a $1.3B fund to produce more APIs domestically. The fund will cover infrastructure and financial incentives for up to 20% of incremental sales value over a period of eight years.
Quick Hits: India Weans Itself off Chinese APIs
India is investing $1.3B to decrease its dependence on Chinese APIs amid supply concerns related to the coronavirus outbreak.
Mar 27, 2020
Sustainable Healthcare Packaging Solutions That Work
Industry leaders share proven strategies for reducing packaging emissions by up to 70% while meeting safety and regulatory requirements.
Read More
Start 2026 with Smarter Packaging for Life Sciences at PACK EXPO East!
Be the first to find what’s next in packaging for life sciences at PACK EXPO East. See solutions from 500 exhibitors, gain inspiration in free educational sessions and uncover new ideas for your industry and beyond—all in one trip to Philadelphia.
REGISTER NOW & SAVE
Downloads
